OTCM

OTC Markets Group Inc.

 
Class A Common Stock Alternative Reporting
OTCQX U.S. Premier
 

OTC Disclosure & News Service

 

OTC Markets Group Welcomes Nuvo Pharmaceuticals to OTCQX

Nov 28, 2017

OTC Disclosure & News Service

- OTC Markets Group Welcomes Nuvo Pharmaceuticals to OTCQX

OTC Markets Group Welcomes Nuvo Pharmaceuticals to OTCQX

PR Newswire

NEW YORK, Nov. 28, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Nuvo Pharmaceuticals Inc (TSX: NRI; OTCQX: NRIFF), a commercial healthcare company, has qualified to trade on OTCQX® Best Market.  Nuvo Pharmaceuticals upgraded to OTCQX from the Pink® market.

Nuvo Pharmaceuticals begins trading today on OTCQX under the symbol "NRIFF."  U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"Nuvo Pharmaceuticals joins over 100 Canadian companies together representing $30 billion in market capitalization that cross-trade their shares on our OTCQX Best Market," said Jason Paltrowitz, Executive Vice President of OTC Markets Group. "OTCQX enables international companies to efficiently provide U.S. investors with transparent trading and convenient access to their news and financials. We look forward to supporting Nuvo Pharmaceuticals in the U.S. public market."

"Upgrading to OTCQX is an important milestone for the Company, and puts Nuvo Pharmaceuticals Inc. in the same market as many esteemed global companies.  The enhanced visibility and greater exposure to US retail and institutional investors resulting from the OTCQX market is part of our strategy to expand our shareholder base and increase shareholder value," said Jesse Ledger, President and CEO of Nuvo Pharmaceuticals Inc.

Nuvo Pharmaceuticals was sponsored for OTCQX by Troutman Sanders LLP, a qualified third-party firm responsible for providing guidance on OTCQX requirements and recommending membership. 

About Nuvo Pharmaceuticals Inc
Nuvo is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities. Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch. Pennsaid 2% is sold in the U.S. by Horizon Pharma plc and is available for partnering in certain other territories around the world. Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA, Health Canada and E.U. approved manufacturing facility in Varennes, Québec.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities.  Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

OTC Markets Group logo. (PRNewsFoto/OTC Markets Group)

View original content with multimedia:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-nuvo-pharmaceuticals-to-otcqx-300561914.html

SOURCE OTC Markets Group Inc.

Copyright © 2017 PR Newswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.